CARGO Therapeutics EBIT

The latest EBIT for CRGX is $-150M as of June 2025. That compares with $-150M in the prior-year period — up 1.4% year over year. That is below the sector sector average of $-69M. Investors often review this figure alongside CARGO Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRGX's EBIT moved from $-150M to $-150M — a 1.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CARGO Therapeutics's operating scale or balance-sheet position.

Against its sector companies, CRGX currently prints $-150M for EBIT, while the sector average sits near $-69M. That is roughly 118.1% below the sector mean. Large gaps often invite a closer look at CARGO Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-150M for CRGX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-69M. Explore the charts below for those layers of context.

After noting CRGX's EBIT ($-150M), review year-over-year change from $-150M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.